surprisingly , the two dihydropyridine class calcium channel blockers , nimodipine and nicardipine , also failed to enhance cisplatin 's antitumor actions despite the fact that their specificity and kinetics for binding to the dihydropyridine receptor component of the calcium channel favors them ( nimodipine and nicardipine ) over nifedipine .
C2945601
dihydropyridine
C0028005
nicardipine